{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-088684","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.190989+00:00","generated_at":"2026-06-24T01:25:04.272497+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VYNE's FMX114 Phase 2a AD trial misses primary endpoint; shareholders reject reverse stock split","bullets":["Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis did not meet primary endpoint (ADSI change at week 4, p=0.228).","Mean ADSI reduction -60.62% for FMX114 vs -51.32% for vehicle; not statistically significant.","CEO disappointed; company will evaluate pipeline and prioritization.","Cash ~$43M as of June 30, 2022; $5M payment due Jan 2023 from MST franchise sale.","Shareholders voted against reverse stock split (needed >28.9M votes, got 23.7M for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-088684","json":"https://secwatch.observer/filing/0001104659-22-088684.json","markdown":"https://secwatch.observer/filing/0001104659-22-088684.md","text":"https://secwatch.observer/filing/0001104659-22-088684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922088684/0001104659-22-088684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922088684/tm2222986d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:25:04.272497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}